title: Phase II trial of paclitaxel plus gemcitabine in patients with locally advanced or metastatic non-small-cell lung cancer.
abstract: OBJECTIVE
  Given the cisplatin-related myelotoxicity and nonhematologic toxicities, we were prompted to undertake a study of the noncisplatin combination of paclitaxel plus gemcitabine to evaluate the efficacy, tolerance, and survival of this combination in patients with locally advanced and metastatic non-small-cell lung cancer (NSCLC).
  
  
  METHODS
  Patients received gemcitabine 2,000 mg/m(2) and paclitaxel 150 mg/m(2) on days 1 and 15 of a 28-day cycle, for a maximum of eight cycles.
  
  
  RESULTS
  Between December 1997 and June 1998, 89 untreated NSCLC patients were enrolled; 30 (34%) had stage IIIB disease (23 with malignant pleural effusion and seven without), and 59 (66%) had stage IV disease. Eighty-six percent of patients had a performance status of 0 or 1. The median number of cycles administered was four (range, one to eight cycles). The mean dose-intensity for both paclitaxel and gemcitabine was nearly 100%. Hematologic and nonhematologic toxicities were mild. Thirty-eight patients received second-line chemotherapy after completion of the study. The overall intent-to-treat response rate was 32.2%, with a higher response rate for stage IIIB patients (43.3%) than for stage IV patients (26.3%). Overall median survival was 9.9 months, and 1-year survival was 38.8% (14.2 months for stage IIIB and 7.7 months for stage IV; P =.007). Median survival was 10.2 months for patients with a performance status of 0 or 1 and 4.8 months for patients with a performance status of 2 (P =.007).
  
  
  CONCLUSIONS
  A biweekly paclitaxel/gemcitabine regimen was well tolerated, with an acceptable response rate and a reasonable median survival time, especially in patients with good performance status. It merits further exploration in future studies.
authors.affiliation: Hospital Clínico Lozano Blesa and Hospital Miguel Servet, Zaragoza.
authors.forename: D
authors.initials: D
authors.lastname: Isla
authors.forename: R
authors.initials: R
authors.lastname: Rosell
authors.forename: J J
authors.initials: JJ
authors.lastname: Sánchez
authors.forename: A
authors.initials: A
authors.lastname: Carrato
authors.forename: E
authors.initials: E
authors.lastname: Felip
authors.forename: C
authors.initials: C
authors.lastname: Camps
authors.forename: A
authors.initials: A
authors.lastname: Artal
authors.forename: J L
authors.initials: JL
authors.lastname: González-Larriba
authors.forename: P
authors.initials: P
authors.lastname: Azagra
authors.forename: V
authors.initials: V
authors.lastname: Alberola
authors.forename: C
authors.initials: C
authors.lastname: Martin
authors.forename: B
authors.initials: B
authors.lastname: Massutí
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000401:mortality; D003841:Deoxycytidine / Q000008:administration & dosage* / Q000031:analogs & derivatives; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D017567:Karnofsky Performance Status; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000401:mortality; D008297:Male; D008875:Middle Aged; D009362:Neoplasm Metastasis; D017239:Paclitaxel / Q000008:administration & dosage*; D000093542:Gemcitabine
chemical_list: D003841:Deoxycytidine; D017239:Paclitaxel; D000093542:Gemcitabine